Science 8 June 1984: Vol. 224. no. 4653, pp. 1121 - 1124 DOI: 10.1126/science.6719137

Prev | Table of Contents | Next

Articles

Heterogeneity of the MYCN Oncogene in Neuroblastoma.

J. Theissen, M. Boensch, R. Spitz, D. Betts, S. Stegmaier, H. Christiansen, F. Niggli, F. Schilling, M. Schwab, T. Simon, et al. (2009)
Clin. Cancer Res. 15, 2085-2090
 |  Abstract »  |  Full Text »  |  PDF »

Significance of MYCN Amplification in International Neuroblastoma Staging System Stage 1 and 2 Neuroblastoma: A Report From the International Neuroblastoma Risk Group Database.

R. Bagatell, M. Beck-Popovic, W. B. London, Y. Zhang, A. D.J. Pearson, K. K. Matthay, T. Monclair, P. F. Ambros, and S. L. Cohn (2009)
J. Clin. Oncol. 27, 365-370
 |  Abstract »  |  Full Text »  |  PDF »

Targeting Ornithine Decarboxylase Impairs Development of MYCN-Amplified Neuroblastoma.

R. J. Rounbehler, W. Li, M. A. Hall, C. Yang, M. Fallahi, and J. L. Cleveland (2009)
Cancer Res. 69, 547-553
 |  Abstract »  |  Full Text »  |  PDF »

Presence of 1q gain and absence of 7p gain are new predictors of local or metastatic relapse in localized resectable neuroblastoma.

A. Pezzolo, E. Rossi, S. Gimelli, F. Parodi, F. Negri, M. Conte, A. Pistorio, A. Sementa, V. Pistoia, O. Zuffardi, et al. (2009)
Neuro-oncol 11, 192-200
 |  Abstract »  |  Full Text »  |  PDF »

BDNF splice variants from the second promoter cluster support cell survival of differentiated neuroblastoma upon cytotoxic stress.

B. Gabriele and T. Enrico (2009)
J. Cell Sci. 122, 36-43
 |  Abstract »  |  Full Text »  |  PDF »

Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells.

H. M. Pettersson, A. Pietras, M. Munksgaard Persson, J. Karlsson, L. Johansson, M. C. Shoshan, and S. Pahlman (2009)
Mol. Cancer Ther. 8, 160-170
 |  Abstract »  |  Full Text »  |  PDF »

N-Myc Regulates a Widespread Euchromatic Program in the Human Genome Partially Independent of Its Role as a Classical Transcription Factor.

R. Cotterman, V. X. Jin, S. R. Krig, J. M. Lemen, A. Wey, P. J. Farnham, and P. S. Knoepfler (2008)
Cancer Res. 68, 9654-9662
 |  Abstract »  |  Full Text »  |  PDF »

ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma.

M. D. Hogarty, M. D. Norris, K. Davis, X. Liu, N. F. Evageliou, C. S. Hayes, B. Pawel, R. Guo, H. Zhao, E. Sekyere, et al. (2008)
Cancer Res. 68, 9735-9745
 |  Abstract »  |  Full Text »  |  PDF »

Circulating Methylated-DCR2 Gene in Serum as an Indicator of Prognosis and Therapeutic Efficacy in Patients with MYCN Nonamplified Neuroblastoma.

S. Yagyu, T. Gotoh, T. Iehara, M. Miyachi, Y. Katsumi, S. Tsubai-Shimizu, K. Kikuchi, S. Tamura, K. Tsuchiya, T. Imamura, et al. (2008)
Clin. Cancer Res. 14, 7011-7019
 |  Abstract »  |  Full Text »  |  PDF »

Interleukin-6 and Soluble Interleukin-6 Receptor Levels as Markers of Disease Extent and Prognosis in Neuroblastoma.

R. A. Egler, S. M. Burlingame, J. G. Nuchtern, and H. V. Russell (2008)
Clin. Cancer Res. 14, 7028-7034
 |  Abstract »  |  Full Text »  |  PDF »

Subclassification and Individual Survival Time Prediction from Gene Expression Data of Neuroblastoma Patients by Using CASPAR.

A. Oberthuer, L. Kaderali, Y. Kahlert, B. Hero, F. Westermann, F. Berthold, B. Brors, R. Eils, and M. Fischer (2008)
Clin. Cancer Res. 14, 6590-6601
 |  Abstract »  |  Full Text »  |  PDF »

KIF1B{beta} Functions as a Haploinsufficient Tumor Suppressor Gene Mapped to Chromosome 1p36.2 by Inducing Apoptotic Cell Death.

A. K. Munirajan, K. Ando, A. Mukai, M. Takahashi, Y. Suenaga, M. Ohira, T. Koda, T. Hirota, T. Ozaki, and A. Nakagawara (2008)
J. Biol. Chem. 283, 24426-24434
 |  Abstract »  |  Full Text »  |  PDF »

p73{alpha} isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells.

E. Horvilleur, M. Bauer, D. Goldschneider, X. Mergui, A. de La Motte, J. Benard, S. Douc-Rasy, and D. Cappellen (2008)
Nucleic Acids Res. 36, 4222-4232
 |  Abstract »  |  Full Text »  |  PDF »

Impact of a Single Nucleotide Polymorphism in the MDM2 Gene on Neuroblastoma Development and Aggressiveness: Results of a Pilot Study on 239 Patients.

S. Cattelani, R. Defferrari, S. Marsilio, R. Bussolari, O. Candini, F. Corradini, G. Ferrari-Amorotti, C. Guerzoni, L. Pecorari, C. Menin, et al. (2008)
Clin. Cancer Res. 14, 3248-3253
 |  Abstract »  |  Full Text »  |  PDF »

Clinical Significance of MYCN Amplification and Ploidy in Favorable-Stage Neuroblastoma: A Report From the Children's Oncology Group.

J. Schneiderman, W. B. London, G. M. Brodeur, R. P. Castleberry, A. T. Look, and S. L. Cohn (2008)
J. Clin. Oncol. 26, 913-918
 |  Abstract »  |  Full Text »  |  PDF »

Targeting the Phosphoinositide 3-Kinase Isoform p110{delta} Impairs Growth and Survival in Neuroblastoma Cells.

D. Boller, A. Schramm, K. T. Doepfner, T. Shalaby, A. O. von Bueren, A. Eggert, M. A. Grotzer, and A. Arcaro (2008)
Clin. Cancer Res. 14, 1172-1181
 |  Abstract »  |  Full Text »  |  PDF »

N-myc coordinates retinal growth with eye size during mouse development.

R. A.P. Martins, F. Zindy, S. Donovan, J. Zhang, S. Pounds, A. Wey, P. S. Knoepfler, R. N. Eisenman, M. F. Roussel, and M. A. Dyer (2008)
Genes & Dev. 22, 179-193
 |  Abstract »  |  Full Text »  |  PDF »

Genes Proximal and Distal to MYCN Are Highly Expressed in Human Neuroblastoma as Visualized by Comparative Expressed Sequence Hybridization.

C. Stock, E. Bozsaky, F. Watzinger, U. Poetschger, L. Orel, T. Lion, A. Kowalska, and P. F. Ambros (2008)
Am. J. Pathol. 172, 203-214
 |  Abstract »  |  Full Text »  |  PDF »

Bone Morphogenetic Protein 2 Opposes Shh-mediated Proliferation in Cerebellar Granule Cells through a TIEG-1-based Regulation of Nmyc.

R. Alvarez-Rodriguez, M. Barzi, J. Berenguer, and S. Pons (2007)
J. Biol. Chem. 282, 37170-37180
 |  Abstract »  |  Full Text »  |  PDF »

High Skp2 Expression Characterizes High-Risk Neuroblastomas Independent of MYCN Status.

F. Westermann, K.-O. Henrich, J. S. Wei, W. Lutz, M. Fischer, R. Konig, R. Wiedemeyer, V. Ehemann, B. Brors, K. Ernestus, et al. (2007)
Clin. Cancer Res. 13, 4695-4703
 |  Abstract »  |  Full Text »  |  PDF »

N-MYC Regulates Focal Adhesion Kinase Expression in Human Neuroblastoma.

E. A. Beierle, A. Trujillo, A. Nagaram, E. V. Kurenova, R. Finch, X. Ma, J. Vella, W. G. Cance, and V. M. Golubovskaya (2007)
J. Biol. Chem. 282, 12503-12516
 |  Abstract »  |  Full Text »  |  PDF »

Fractalkine (CX3CL1)- and Interleukin-2-Enriched Neuroblastoma Microenvironment Induces Eradication of Metastases Mediated by T Cells and Natural Killer Cells.

Y. Zeng, N. Huebener, S. Fest, S. Weixler, U. Schroeder, G. Gaedicke, R. Xiang, A. Schramm, A. Eggert, R. A. Reisfeld, et al. (2007)
Cancer Res. 67, 2331-2338
 |  Abstract »  |  Full Text »  |  PDF »

Differential Patterns of MicroRNA Expression in Neuroblastoma Are Correlated with Prognosis, Differentiation, and Apoptosis.

Y. Chen and R. L. Stallings (2007)
Cancer Res. 67, 976-983
 |  Abstract »  |  Full Text »  |  PDF »

The Coamplification Pattern of the MYCN Amplicon Is an Invariable Attribute of Most MYCN-Amplified Human Neuroblastomas.

A. Weber, S. Starke, E. Bergmann, and H. Christiansen (2006)
Clin. Cancer Res. 12, 7316-7321
 |  Abstract »  |  Full Text »  |  PDF »

Customized Oligonucleotide Microarray Gene Expression-Based Classification of Neuroblastoma Patients Outperforms Current Clinical Risk Stratification.

A. Oberthuer, F. Berthold, P. Warnat, B. Hero, Y. Kahlert, R. Spitz, K. Ernestus, R. Konig, S. Haas, R. Eils, et al. (2006)
J. Clin. Oncol. 24, 5070-5078
 |  Abstract »  |  Full Text »  |  PDF »

Molecular Therapy of Human Neuroblastoma Cells Using Auger Electrons of 111In-Labeled N-myc Antisense Oligonucleotides.

N. Watanabe, H. Sawai, I. Ogihara-Umeda, S. Tanada, E. E. Kim, Y. Yonekura, and Y. Sasaki (2006)
J. Nucl. Med. 47, 1670-1677
 |  Abstract »  |  Full Text »  |  PDF »

Cellular Retinoic Acid-Binding Protein II Is a Direct Transcriptional Target of MycN in Neuroblastoma.

A. Gupta, B. R.G. Williams, S. M. Hanash, and J. Rawwas (2006)
Cancer Res. 66, 8100-8108
 |  Abstract »  |  Full Text »  |  PDF »

Inhibition of Phosphatidylinositol 3-Kinase Destabilizes Mycn Protein and Blocks Malignant Progression in Neuroblastoma.

L. Chesler, C. Schlieve, D. D. Goldenberg, A. Kenney, G. Kim, A. McMillan, K. K. Matthay, D. Rowitch, and W. A. Weiss (2006)
Cancer Res. 66, 8139-8146
 |  Abstract »  |  Full Text »  |  PDF »

High-Risk Neuroblastoma Treated With Tandem Autologous Peripheral-Blood Stem Cell-Supported Transplantation: Long-Term Survival Update.

R. E. George, S. Li, C. Medeiros-Nancarrow, D. Neuberg, K. Marcus, R. C. Shamberger, M. Pulsipher, S. A. Grupp, and L. Diller (2006)
J. Clin. Oncol. 24, 2891-2896
 |  Abstract »  |  Full Text »  |  PDF »

Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number..

Q. Wang, S. Diskin, E. Rappaport, E. Attiyeh, Y. Mosse, D. Shue, E. Seiser, J. Jagannathan, S. Shusterman, M. Bansal, et al. (2006)
Cancer Res. 66, 6050-6062
 |  Abstract »  |  Full Text »  |  PDF »

Loss in Chromosome 11q Identifies Tumors with Increased Risk for Metastatic Relapses in Localized and 4S Neuroblastoma..

R. Spitz, B. Hero, T. Simon, and F. Berthold (2006)
Clin. Cancer Res. 12, 3368-3373
 |  Abstract »  |  Full Text »  |  PDF »

High-Resolution Analysis of Chromosomal Breakpoints and Genomic Instability Identifies PTPRD as a Candidate Tumor Suppressor Gene in Neuroblastoma..

R. L. Stallings, P. Nair, J. M. Maris, D. Catchpoole, M. McDermott, A. O'Meara, and F. Breatnach (2006)
Cancer Res. 66, 3673-3680
 |  Abstract »  |  Full Text »  |  PDF »

The MYCN Enigma: Significance of MYCN Expression in Neuroblastoma..

X. X. Tang, H. Zhao, B. Kung, D. Y. Kim, S. L. Hicks, S. L. Cohn, N.-K. Cheung, R. C. Seeger, A. E. Evans, and N. Ikegaki (2006)
Cancer Res. 66, 2826-2833
 |  Abstract »  |  Full Text »  |  PDF »

Reduced Expression of CAMTA1 Correlates with Adverse Outcome in Neuroblastoma Patients.

K.-O. Henrich, M. Fischer, D. Mertens, A. Benner, R. Wiedemeyer, B. Brors, A. Oberthuer, F. Berthold, J. S. Wei, J. Khan, et al. (2006)
Clin. Cancer Res. 12, 131-138
 |  Abstract »  |  Full Text »  |  PDF »

Outcomes of Children With Intermediate-Risk Neuroblastoma After Treatment Stratified by MYCN Status and Tumor Cell Ploidy.

R. Bagatell, P. Rumcheva, W. B. London, S. L. Cohn, A. T. Look, G. M. Brodeur, C. Frantz, V. Joshi, P. Thorner, P.V. Rao, et al. (2005)
J. Clin. Oncol. 23, 8819-8827
 |  Abstract »  |  Full Text »  |  PDF »

Hyperdiploidy Plus Nonamplified MYCN Confers a Favorable Prognosis in Children 12 to 18 Months Old With Disseminated Neuroblastoma: A Pediatric Oncology Group Study.

R. E. George, W. B. London, S. L. Cohn, J. M. Maris, C. Kretschmar, L. Diller, G. M. Brodeur, R. P. Castleberry, and A. T. Look (2005)
J. Clin. Oncol. 23, 6466-6473
 |  Abstract »  |  Full Text »  |  PDF »

Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group.

W.B. London, R.P. Castleberry, K.K. Matthay, A.T. Look, R.C. Seeger, H. Shimada, P. Thorner, G. Brodeur, J.M. Maris, C.P. Reynolds, et al. (2005)
J. Clin. Oncol. 23, 6459-6465
 |  Abstract »  |  Full Text »  |  PDF »

Favorable Prognosis for Patients 12 to 18 Months of Age With Stage 4 Nonamplified MYCN Neuroblastoma: A Children's Cancer Group Study.

M. L. Schmidt, A. Lal, R. C. Seeger, J. M. Maris, H. Shimada, M. O'Leary, R. B. Gerbing, and K. K. Matthay (2005)
J. Clin. Oncol. 23, 6474-6480
 |  Abstract »  |  Full Text »  |  PDF »

Age at Diagnosis and Prognosis in Children With Neuroblastoma.

A. E. Evans and G. J. D'Angio (2005)
J. Clin. Oncol. 23, 6443-6444
 |  Full Text »  |  PDF »

Prediction of MYCN Amplification in Neuroblastoma Using Serum DNA and Real-Time Quantitative Polymerase Chain Reaction.

T. Gotoh, H. Hosoi, T. Iehara, Y. Kuwahara, S. Osone, K. Tsuchiya, M. Ohira, A. Nakagawara, H. Kuroda, and T. Sugimoto (2005)
J. Clin. Oncol. 23, 5205-5210
 |  Abstract »  |  Full Text »  |  PDF »

Region-specific detection of neuroblastoma loss of heterozygosity at multiple loci simultaneously using a SNP-based tag-array platform.

J. M. Maris, G. Hii, C. A. Gelfand, S. Varde, P. S. White, E. Rappaport, S. Surrey, and P. Fortina (2005)
Genome Res. 15, 1168-1176
 |  Abstract »  |  Full Text »  |  PDF »

LMO3 Interacts with Neuronal Transcription Factor, HEN2, and Acts as an Oncogene in Neuroblastoma.

M. Aoyama, T. Ozaki, H. Inuzuka, D. Tomotsune, J. Hirato, Y. Okamoto, H. Tokita, M. Ohira, and A. Nakagawara (2005)
Cancer Res. 65, 4587-4597
 |  Abstract »  |  Full Text »  |  PDF »

Shc Family Expression in Neuroblastoma: High Expression of shcC Is Associated with a Poor Prognosis in Advanced Neuroblastoma.

E. Terui, T. Matsunaga, H. Yoshida, K. Kouchi, H. Kuroda, T. Hishiki, T. Saito, S.-i. Yamada, H. Shirasawa, and N. Ohnuma (2005)
Clin. Cancer Res. 11, 3280-3287
 |  Abstract »  |  Full Text »  |  PDF »

Activin A Suppresses Neuroblastoma Xenograft Tumor Growth via Antimitotic and Antiangiogenic Mechanisms.

E. Panopoulou, C. Murphy, H. Rasmussen, E. Bagli, E. K. Rofstad, and T. Fotsis (2005)
Cancer Res. 65, 1877-1886
 |  Abstract »  |  Full Text »  |  PDF »

Association of Epigenetic Inactivation of RASSF1A with Poor Outcome in Human Neuroblastoma.

Q. Yang, P. Zage, D. Kagan, Y. Tian, R. Seshadri, H. R. Salwen, S. Liu, A. Chlenski, and S. L. Cohn (2004)
Clin. Cancer Res. 10, 8493-8500
 |  Abstract »  |  Full Text »  |  PDF »

Response to Paclitaxel, Topotecan, and Topotecan-Cyclophosphamide in Children With Untreated Disseminated Neuroblastoma Treated in an Upfront Phase II Investigational Window: A Pediatric Oncology Group Study.

C. S. Kretschmar, M. Kletzel, K. Murray, P. Thorner, V. Joshi, R. Marcus, E. I. Smith, W. B. London, and R. Castleberry (2004)
J. Clin. Oncol. 22, 4119-4126
 |  Abstract »  |  Full Text »  |  PDF »

GABAergic System Gene Expression Predicts Clinical Outcome in Patients With Neuroblastoma.

S. S. Roberts, M. Mori, P. Pattee, J. Lapidus, R. Mathews, J. P. O'Malley, Y. C. Hsieh, M. A. Turner, Z. Wang, Q. Tian, et al. (2004)
J. Clin. Oncol. 22, 4127-4134
 |  Abstract »  |  Full Text »  |  PDF »

Targeted Expression of Human MYCN Selectively Causes Pancreatic Neuroendocrine Tumors in Transgenic Zebrafish.

H. W. Yang, J. L. Kutok, N. H. Lee, H. Y. Piao, C. D. M. Fletcher, J. P. Kanki, and A. T. Look (2004)
Cancer Res. 64, 7256-7262
 |  Abstract »  |  Full Text »  |  PDF »

Scintigraphic Response by 123I-Metaiodobenzylguanidine Scan Correlates With Event-Free Survival in High-Risk Neuroblastoma.

H. M. Katzenstein, S. L. Cohn, R. M. Shore, D. M.E. Bardo, P. R. Haut, M. Olszewski, J. Schmoldt, D. Liu, A. W. Rademaker, and M. Kletzel (2004)
J. Clin. Oncol. 22, 3909-3915
 |  Abstract »  |  Full Text »  |  PDF »

Prediction of Clinical Outcome Using Gene Expression Profiling and Artificial Neural Networks for Patients with Neuroblastoma.

J. S. Wei, B. T. Greer, F. Westermann, S. M. Steinberg, C.-G. Son, Q.-R. Chen, C. C. Whiteford, S. Bilke, A. L. Krasnoselsky, N. Cenacchi, et al. (2004)
Cancer Res. 64, 6883-6891
 |  Abstract »  |  Full Text »  |  PDF »

Nitric oxide negatively regulates proliferation and promotes neuronal differentiation through N-Myc downregulation.

E. Ciani, S. Severi, A. Contestabile, R. Bartesaghi, and A. Contestabile (2004)
J. Cell Sci. 117, 4727-4737
 |  Abstract »  |  Full Text »  |  PDF »

Hepatocyte Growth Factor/c-Met Signaling Promotes the Progression of Experimental Human Neuroblastomas.

M. Hecht, M. Papoutsi, H. D. Tran, J. Wilting, and L. Schweigerer (2004)
Cancer Res. 64, 6109-6118
 |  Abstract »  |  Full Text »  |  PDF »

Coamplification of DDX1 Correlates With an Improved Survival Probability in Children With MYCN-Amplified Human Neuroblastoma.

A. Weber, P. Imisch, E. Bergmann, and H. Christiansen (2004)
J. Clin. Oncol. 22, 2681-2690
 |  Abstract »  |  Full Text »  |  PDF »

Methylation-Associated Silencing of the Heat Shock Protein 47 Gene in Human Neuroblastoma.

Q. Yang, S. Liu, Y. Tian, C. Hasan, D. Kersey, H. R. Salwen, A. Chlenski, E. J. Perlman, and S. L. Cohn (2004)
Cancer Res. 64, 4531-4538
 |  Abstract »  |  Full Text »  |  PDF »

Nucleoside Diphosphate Kinase A/nm23-H1 Promotes Metastasis of NB69-Derived Human Neuroblastoma.

M. A.E. Almgren, K. C. E. Henriksson, J. Fujimoto, and C. L. Chang (2004)
Mol. Cancer Res. 2, 387-394
 |  Abstract »  |  Full Text »  |  PDF »

Identification and Characterization of a Novel Gene, C13orf25, as a Target for 13q31-q32 Amplification in Malignant Lymphoma.

A. Ota, H. Tagawa, S. Karnan, S. Tsuzuki, A. Karpas, S. Kira, Y. Yoshida, and M. Seto (2004)
Cancer Res. 64, 3087-3095
 |  Abstract »  |  Full Text »  |  PDF »

Maternal Medication Use and Neuroblastoma in Offspring.

M. N. Cook, A. F. Olshan, H. A. Guess, D. A. Savitz, C. Poole, J. Blatt, M. L. Bondy, and B. H. Pollock (2004)
Am. J. Epidemiol. 159, 721-731
 |  Abstract »  |  Full Text »  |  PDF »

Coexpression of Insulin Receptor-Related Receptor and Insulin-Like Growth Factor 1 Receptor Correlates with Enhanced Apoptosis and Dedifferentiation in Human Neuroblastomas.

A. Weber, C. Huesken, E. Bergmann, W. Kiess, N. M. Christiansen, and H. Christiansen (2003)
Clin. Cancer Res. 9, 5683-5692
 |  Abstract »  |  Full Text »  |  PDF »

Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma.

C. A. Burkhart, A. J. Cheng, J. Madafiglio, M. Kavallaris, M. Mili, G. M. Marshall, W. A. Weiss, L. M. Khachigian, M. D. Norris, and M. Haber (2003)
J Natl Cancer Inst 95, 1394-1403
 |  Abstract »  |  Full Text »  |  PDF »

Genome-wide Array CGH Analysis of Murine Neuroblastoma Reveals Distinct Genomic Aberrations which Parallel those in Human Tumors.

C. S. Hackett, J. G. Hodgson, M. E. Law, J. Fridlyand, K. Osoegawa, P. J. de Jong, N. J. Nowak, D. Pinkel, D. G. Albertson, A. Jain, et al. (2003)
Cancer Res. 63, 5266-5273
 |  Abstract »  |  Full Text »  |  PDF »

Expression of a MYCN-interacting Isoform of the Tumor Suppressor BIN1 Is Reduced in Neuroblastomas with Unfavorable Biological Features.

T. Tajiri, X. Liu, P. M. Thompson, S. Tanaka, S. Suita, H. Zhao, J. M. Maris, G. C. Prendergast, and M. D. Hogarty (2003)
Clin. Cancer Res. 9, 3345-3355
 |  Abstract »  |  Full Text »  |  PDF »

Quality Assessment of Genetic Markers Used for Therapy Stratification.

I.M. Ambros, J. Benard, M. Boavida, N. Bown, H. Caron, V. Combaret, J. Couturier, C. Darnfors, O. Delattre, J. Freeman-Edward, et al. (2003)
J. Clin. Oncol. 21, 2077-2084
 |  Abstract »  |  Full Text »  |  PDF »

Advances in the Diagnosis and Treatment of Neuroblastoma.

J. L. Weinstein, H. M. Katzenstein, and S. L. Cohn (2003)
Oncologist 8, 278-292
 |  Abstract »  |  Full Text »  |  PDF »

Amplification and Overexpression of the L-MYC Proto-Oncogene in Ovarian Carcinomas.

R. Wu, L. Lin, D. G. Beer, L. H. Ellenson, B. J. Lamb, J.-M. Rouillard, R. Kuick, S. Hanash, D. R. Schwartz, E. R. Fearon, et al. (2003)
Am. J. Pathol. 162, 1603-1610
 |  Abstract »  |  Full Text »  |  PDF »

Full-Length Telomerase Reverse Transcriptase Messenger RNA Is an Independent Prognostic Factor in Neuroblastoma.

M. Krams, B. Hero, F. Berthold, R. Parwaresch, D. Harms, and P. Rudolph (2003)
Am. J. Pathol. 162, 1019-1026
 |  Abstract »  |  Full Text »  |  PDF »

E2F Proteins Regulate MYCN Expression in Neuroblastomas.

V. Strieder and W. Lutz (2003)
J. Biol. Chem. 278, 2983-2989
 |  Abstract »  |  Full Text »  |  PDF »

Deletions in Chromosome Arms 3p and 11q Are New Prognostic Markers in Localized and 4s Neuroblastoma.

R. Spitz, B. Hero, K. Ernestus, and F. Berthold (2003)
Clin. Cancer Res. 9, 52-58
 |  Abstract »  |  Full Text »  |  PDF »

Evidence for a Hereditary Neuroblastoma Predisposition Locus at Chromosome 16p12-13.

J. M. Maris, M. J. Weiss, Y. Mosse, G. Hii, C. Guo, P. S. White, M. D. Hogarty, T. Mirensky, G. M. Brodeur, T. R. Rebbeck, et al. (2002)
Cancer Res. 62, 6651-6658
 |  Abstract »  |  Full Text »  |  PDF »

MS-27-275, an Inhibitor of Histone Deacetylase, Has Marked in Vitro and in Vivo Antitumor Activity against Pediatric Solid Tumors.

J. Jaboin, J. Wild, H. Hamidi, C. Khanna, C. J. Kim, R. Robey, S. E. Bates, and C. J. Thiele (2002)
Cancer Res. 62, 6108-6115
 |  Abstract »  |  Full Text »  |  PDF »

From the Archives of the AFIP : Neuroblastoma, Ganglioneuroblastoma, and Ganglioneuroma: Radiologic-Pathologic Correlation.

G. J. Lonergan, C. M. Schwab, E. S. Suarez, and C. L. Carlson (2002)
RadioGraphics 22, 911-934
 |  Abstract »  |  Full Text »  |  PDF »

Novel Regions of Allelic Imbalance Identified by Genome-wide Analysis of Neuroblastoma.

J. Mora, N.-K. V. Cheung, S. Oplanich, L. Chen, and W. L. Gerald (2002)
Cancer Res. 62, 1761-1767
 |  Abstract »  |  Full Text »  |  PDF »

N-myc Promotes Survival and Induces S-Phase Entry of Postmitotic Sympathetic Neurons.

K. Wartiovaara, F. Barnabe-Heider, F. D. Miller, and D. R. Kaplan (2002)
J. Neurosci. 22, 815-824
 |  Abstract »  |  Full Text »  |  PDF »

Neuroblastoma tumour genetics: clinical and biological aspects.

N Bown (2001)
J. Clin. Pathol. 54, 897-910
 |  Abstract »  |  Full Text »  |  PDF »

Independent Amplification of Two Gene Clusters on Chromosome 4 in Rat Endometrial Cancer: Identification and Molecular Characterization.

A. Walentinsson, K. Helou, V. Wallenius, H. J. Hedrich, C. Szpirer, and G. Levan (2001)
Cancer Res. 61, 8263-8273
 |  Abstract »  |  Full Text »  |  PDF »

Regulation of Telomerase Activity by Alternate Splicing of Human Telomerase Reverse Transcriptase mRNA in a Subset of Neuroblastomas.

M. Krams, A. Claviez, K. Heidorn, G. Krupp, R. Parwaresch, D. Harms, and P. Rudolph (2001)
Am. J. Pathol. 159, 1925-1932
 |  Abstract »  |  Full Text »  |  PDF »

p16/p14ARF Cell Cycle Regulatory Pathways in Primary Neuroblastoma: p16 Expression Is Associated with Advanced Stage Disease.

M. Omura-Minamisawa, M. B. Diccianni, R. C. Chang, A. Batova, L. J. Bridgeman, J. Schiff, S. L. Cohn, W. B. London, and A. L. Yu (2001)
Clin. Cancer Res. 7, 3481-3490
 |  Abstract »  |  Full Text »  |  PDF »

Association of Human DEAD Box Protein DDX1 with a Cleavage Stimulation Factor Involved in 3'-End Processing of Pre-mRNA.

S. Bleoo, X. Sun, M. J. Hendzel, J. M. Rowe, M. Packer, and R. Godbout (2001)
Mol. Biol. Cell 12, 3046-3059
 |  Abstract »  |  Full Text »  |  PDF »

Expression of the cdc25B mRNA Correlated with that of N-myc in Neuroblastoma.

Y. Sato, H. Sasaki, S. Kondo, I. Fukai, M. Kiriyama, Y. Yamakawa, and Y. Fujii (2001)
Jpn. J. Clin. Oncol. 31, 428-431
 |  Abstract »  |  Full Text »  |  PDF »

MYC Messenger RNA Expression Predicts Survival Outcome in Childhood Primitive Neuroectodermal Tumor/Medulloblastoma.

M. A. Grotzer, M. D. Hogarty, A. J. Janss, X. Liu, H. Zhao, A. Eggert, L. N. Sutton, L. B. Rorke, G. M. Brodeur, and P. C. Phillips (2001)
Clin. Cancer Res. 7, 2425-2433
 |  Abstract »  |  Full Text »  |  PDF »

Parental Occupational Exposures to Chemicals and Incidence of Neuroblastoma in Offspring.

A. J. De Roos, A. F. Olshan, K. Teschke, C. Poole, D. A. Savitz, J. Blatt, M. L. Bondy, and B. H. Pollock (2001)
Am. J. Epidemiol. 154, 106-114
 |  Abstract »  |  Full Text »  |  PDF »

Combined Automatic Immunological and Molecular Cytogenetic Analysis Allows Exact Identification and Quantification of Tumor Cells in the Bone Marrow.

G. Mehes, A. Luegmayr, I. M. Ambros, R. Ladenstein, and P. F. Ambros (2001)
Clin. Cancer Res. 7, 1969-1975
 |  Abstract »  |  Full Text »  |  PDF »

Molecular Genetics of Neuroblastoma and the Implications for Clinical Management: A Review of the MSKCC Experience.

J. Mora, W. L. Gerald, J. Qin, and N.-K. V. Cheung (2001)
Oncologist 6, 263-268
 |  Abstract »  |  Full Text »  |  PDF »

Circulating Neuroblastoma Cells Detected by Reverse Transcriptase Polymerase Chain Reaction for Tyrosine Hydroxylase mRNA Are an Independent Poor Prognostic Indicator in Stage 4 Neuroblastoma in Children Over 1 Year.

S. A. Burchill, I. J. Lewis, K. R. Abrams, R. Riley, J. Imeson, A. D.J. Pearson, R. Pinkerton, and P. Selby (2001)
J. Clin. Oncol. 19, 1795-1801
 |  Abstract »  |  Full Text »  |  PDF »

Treatment and Outcome of 83 Children With Intraspinal Neuroblastoma: The Pediatric Oncology Group Experience.

H. M. Katzenstein, P. M. Kent, W. B. London, and S. L. Cohn (2001)
J. Clin. Oncol. 19, 1047-1055
 |  Abstract »  |  Full Text »  |  PDF »

Inhibition of N-myc Expression and Induction of Apoptosis by Iron Chelation in Human Neuroblastoma Cells.

L. Fan, J. Iyer, S. Zhu, K. K. Frick, R. K. Wada, A. E. Eskenazi, P. E. Berg, N. Ikegaki, R. H. Kennett, and C. N. Frantz (2001)
Cancer Res. 61, 1073-1079
 |  Abstract »  |  Full Text »

MYCN Expression in Neuroblastoma: A Mixed Message?.

K. K. Matthay (2000)
J. Clin. Oncol. 18, 3591-3594
 |  Full Text »  |  PDF »

MYCN Expression Is Not Prognostic of Adverse Outcome in Advanced-Stage Neuroblastoma With Nonamplified MYCN.

S. L. Cohn, W. B. London, D. Huang, H. M. Katzenstein, H. R. Salwen, T. Reinhart, J. Madafiglio, G. M. Marshall, M. D. Norris, and M. Haber (2000)
J. Clin. Oncol. 18, 3604-3613
 |  Abstract »  |  Full Text »  |  PDF »

Quantitative Determination of sst2 Gene Expression in Neuroblastoma Tumor Predicts Patient Outcome.

C. C. Raggi, M. Maggi, D. Renzi, A. Calabrò, M. L. Bagnoni, P. Scaruffi, G. P. Tonini, M. Pazzagli, B. De Bernardi, G. Bernini, et al. (2000)
J. Clin. Endocrinol. Metab. 85, 3866-3873
 |  Abstract »  |  Full Text »

Distinct patterns of alteration of myc genes associated with integration of human papillomavirus type 16 or type 45 DNA in two genital tumours.

X. Sastre-Garau, M. Favre, J. Couturier, and G. Orth (2000)
J. Gen. Virol. 81, 1983-1993
 |  Abstract »  |  Full Text »

Enhanced Expression of N-myc Messenger RNA in Neuroblastomas Found by Mass Screening.

T. Matsunaga, H. Shirasawa, T. Hishiki, H. Yoshida, K. Kouchi, Y. Ohtsuka, K. Kawamura, T. Etoh, and N. Ohnuma (2000)
Clin. Cancer Res. 6, 3199-3204
 |  Abstract »  |  Full Text »

Telomerase Activity and Telomerase Subunits Gene Expression Patterns in Neuroblastoma: A Molecular and Immunohistochemical Study Establishing Prognostic Tools for Fresh-Frozen and Paraffin-Embedded Tissues.

C. Poremba, C. Scheel, B. Hero, H. Christiansen, K.-L. Schaefer, J.-i. Nakayama, F. Berthold, H. Juergens, W. Boecker, and B. Dockhorn-Dworniczak (2000)
J. Clin. Oncol. 18, 2582-2592
 |  Abstract »  |  Full Text »  |  PDF »

Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Children's Cancer Group Study.

J. M. Maris, M. J. Weiss, C. Guo, R. B. Gerbing, D. O. Stram, P. S. White, M. D. Hogarty, E. P. Sulman, P. M. Thompson, J. N. Lukens, et al. (2000)
J. Clin. Oncol. 18, 1888-1899
 |  Abstract »  |  Full Text »  |  PDF »

Genome-wide Screen for Allelic Imbalance in a Mouse Model for Neuroblastoma.

W. A. Weiss, T. Godfrey, C. Francisco, and J. M. Bishop (2000)
Cancer Res. 60, 2483-2487
 |  Abstract »  |  Full Text »

Lysis of MYCN-amplified Neuroblastoma Cells by MYCN Peptide-specific Cytotoxic T Lymphocytes.

A. K. Sarkar and J. G. Nuchtern (2000)
Cancer Res. 60, 1908-1913
 |  Abstract »  |  Full Text »

Biologic Factors Determine Prognosis in Infants With Stage IV Neuroblastoma: A Prospective Children’s Cancer Group Study.

M. L. Schmidt, J. N. Lukens, R. C. Seeger, G. M. Brodeur, H. Shimada, R. B. Gerbing, D. O. Stram, C. Perez, G. M. Haase, and K. K. Matthay (2000)
J. Clin. Oncol. 18, 1260-1268
 |  Abstract »  |  Full Text »  |  PDF »

TrkC Expression Predicts Good Clinical Outcome in Primitive Neuroectodermal Brain Tumors.

M. A. Grotzer, A. J. Janss, K.-M. Fung, J. A. Biegel, L. N. Sutton, L. B. Rorke, H. Zhao, A. Cnaan, P. C. Phillips, V. M.-Y. Lee, et al. (2000)
J. Clin. Oncol. 18, 1027
 |  Abstract »  |  Full Text »  |  PDF »

Tumor progression and metastasis.

J. Yokota (2000)
Carcinogenesis 21, 497-503
 |  Abstract »  |  Full Text »  |  PDF »

Biologic Variables in the Outcome of Stages I and II Neuroblastoma Treated With Surgery as Primary Therapy: A Children’s Cancer Group Study.

C. A. Perez, K. K. Matthay, J. B. Atkinson, R. C. Seeger, H. Shimada, G. M. Haase, D. O. Stram, R. B. Gerbing, and J. N. Lukens (2000)
J. Clin. Oncol. 18, 18
 |  Abstract »  |  Full Text »  |  PDF »

To Advertise   |   Find Products